2019 / 01

Next Paper
DOI: 10.24075/brsmu.2019.006

ORIGINAL RESEARCH

Investigating a correlation between the levels of peripheral blood cytokines and the risk for cardiovascular complications in patients with stage II essential hypertension

Radaeva OA1, Simbirtsev AS2
About authors

1 National Research Mordovia State University, Saransk, Russia

2 State Research Institute of Highly Pure Biopreparations, FMBA, St. Petersburg, Russia

Correspondence should be addressed: Olga A. Radaeva
Ulianova 26/a, Saransk, 430030; ur.liam@97_fybwbltv

About paper

Author contribution: Radaeva OA recruited patients, collected blood samples for the study took medical histories, interpreted the study results, and wrote the manuscript. Simbirtsev AS conceived and planned the study, analyzed the obtained data and revised the manuscript.

Received: 2018-07-16 Accepted: 2019-02-27 Published online: 2019-03-07
|
  1. Wenzel U, Turner JE, Krebs C, et al. Immune Mechanisms in Arterial Hypertension. J Am Soc Nephrol. 2016; 27 (3): 677–86.
  2. McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end organ damage. Circ Res. 2015; 116 (6): 1022–33.
  3. Bennardo M, Alibhai F, Tsimakouridze E, et al. Day-night dependence of gene expression and inflammatory responses in the remodeling murine heart post-myocardial. Am J Physiol Regul Integr Comp Physiol. 2016; 311 (6): 1243–54.
  4. Ji Q, Cheng G, Ma N, et al. Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients. Dis Markers 2017; (2017): 7146290. Available from: https://www.hindawi.com/journals/ dm/2017/7146290. PubMed PMID: 28757677.
  5. Nosalski R, McGinnigle E, Siedlinski M, Guzik TJ. Novel Immune Mechanisms in Hypertension and Cardiovascular Risk. Current Cardiovascular Risk Reports. 2017; 11 (4): 12. Available from: https://www.researchgate.net/publication/314274524_Novel_ Immune_Mechanisms_in_Hypertension_and_Cardiovascular_Risk.
  6. Rudemiller NP, Crowley SD. The role of chemokines in hypertension and consequent target organ damage. Pharmacological research. 2017; (119): 404–11.
  7. Schwanekamp JA, Lorts A, Sargent MA, et al. TGFBI functions similar to periostin but is uniquely dispensable during cardiac injury. PLoS ONE. 2017; 12 (7). Available from: https://journals. plos.org/plosone/article?id=10.1371/journal.pone.0181945.
  8. Wang P, He Q, Liu C, et al. Functional polymorphism rs3783553 in the 3’-untranslated region of IL-1A increased the risk of ischemic stroke: A case-control study. Medicine. 2016; 96 (46). Available from: https://www.researchgate.net/publication/320348816_4-bp_ insertiondeletion_rs3783553_polymorphism_within_the_3aposUTR_ of_IL1A_contributes_to_the_risk_of_prostate_cancer_in_a_sample_ of_Iranian_Population.
  9. Carlsson AC, Jansson JH, Söderberg S, et al. Levels of soluble tumor necrosis factor receptor 1 and 2, gender, and risk of myocardial infarction in Northern Sweden. Atherosclerosis. 2018; (272): 41–6.
  10. Huang S, Frangogiannis NG. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br J Pharmacol. 2018; 175 (9): 1377–400.
  11. Itani HA, Harrison DG. Memories that last in hypertension. Am J Physiol Renal Physiol. 2015; 308 (11): F1197–F1199. DOI: 10.1152/ajprenal.00633.2014.
  12. Rucker JA, Crowley SD. The role of macrophages in hypertension and its complications Pflugers Arch. 2017; 469 (3–4): 419–30.
  13. Hartman MHT, Groot HE, et al. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc Med. 2018; 28 (6). DOI: 10.1016/j. tcm.2018.02.003. Available from: https://www.researchgate.net/ publication/260757993_Heart_Failure.
  14. Jia D, Cai M, XiY, et al. Interval exercise training increases LIF expression and prevents myocardial infarction-induced skeletal muscle atrophy in rats. Life Sci. 2018; (193): 77–86.
  15. Van der Heijden T, Bot I, Kuiper J. The IL-12 cytokine family in cardiovascular diseases. Cytokine. 2017; S1043-4666(17)30315- 0. DOI: 10.1016/j.cyto.2017.10.010.
  16. Papageorgiou N, Androulakis E, Papaioannou S, et al. Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease. Amino Acids. 2015; 47 (9): 1741–50.
  17. Shin S, Thapa SK, Fung H-L. Cellular interactions between L-arginine and asymmetric dimethylarginine: Transport and metabolism. PLoS One. 2017; 12 (5): e0178710. DOI: 10.1371/ journal.pone.0178710.
  18. Radaeva OA, Simbirtsev AS. M-CSF, IL-34, VEGF-A kak faktory riska razvitija infarkta miokarda, ostrogo narushenija mozgovogo krovoobrashhenija u bol'nyh jessencial'noj arterial'noj gipertenziej. Rossijskij immunologicheskij zhurnal. 2015; 9 (1): 93–101.
  19. Lee S, Shi XQ, Fan A et al. Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain. Mol Pain. 2018; (14): 1744806918764979. DOI: 10.1177/1744806918764979.